Boehringer Ingelheim will make detailed clinical trial data available to the scientific community

Boehringer IngelheimIn order to add to scientific and medical progress, Boehringer Ingelheim is engaged in a program to make clinical study data and other clinical study related documents more widely accessible for approved products or after termination of a drug development program.

Clinical study reports and other clinical documents can be requested via the Boehringer Ingelheim website, accessible under http://trials.boehringer-ingelheim.com/trial_results.html. This website will also enable researchers to request access to de-identified patient level study data which form the basis of clinical trial findings.

Access to patient level data
Researchers will be granted access via a secure analysis environment after approval of his/her study proposal by an independent external review panel and based on a data sharing agreement. This agreement will include obligations such as the commitment to use the data only for the purpose of the study proposal, to not attempt to identify study participants, to not misuse the data, e. g. for own commercial interests, and to be "transparent" regarding the planned analysis and disclosure of results.

Documents and data to be shared will be redacted by Boehringer Ingelheim as far as this is necessary to protect on the one hand personal data of study participants, study personnel, and Boehringer Ingelheim employees and on the other side to protect Boehringer Ingelheim's commercial confidential information, in particular intellectual property rights.

Data and documents relating to studies initiated back until the year 1998 will be made available.

Publication of all scientific data
In addition, Boehringer Ingelheim confirmed its commitment to publish the scientific results from all sponsored studies in peer reviewed journals and at scientific meetings, regardless of study outcome for all types of clinical studies, Phase I - IV, interventional and non-interventional. Key Publications of Phase III clinical studies are being submitted to indexed, peer-reviewed journals no later than 12 to 18 months after completion of the clinical study.

These commitments were announced already in 2013 and are now being implemented with the website and the formation of a dedicated team to answer requests.

"The free exchange of scientific information is the basis for innovation in medicine. Boehringer Ingelheim as a research-driven pharmaceutical company is committed to the registration of all clinical studies prior to initiation and to disclosing all study results independent of outcome. Going beyond applicable regulatory and legal requirements, we at Boehringer Ingelheim feel it is the right approach and hope it will benefit science", said Dr Christopher Corsico, global Head of Clinical Development, Medicine and Regulatory at Boehringer Ingelheim.

Registration of all clinical studies
Going over and above regulatory and legal requirements, the company will register protocol information for all types of clinical studies on www.ClinicalTrials.gov, incl. Phase I studies in healthy volunteers as well as uncontrolled and non-interventional studies for all prescription and non-prescription drugs performed in any country world-wide. Boehringer Ingelheim commits to extend protocol registration to studies initiated 1998 or later. Starting with studies completing in 2014, the company will extend posting of study results on ClinicalTrials.gov also to products only approved outside the US and from terminated drug development programs.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...